ArticleCancers2019
Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays.
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- BioBERT-powered synergy: advanced bibliometric and molecular insights into prostate cancer bone metastasis.Frontiers in immunology · 2025Pooled it
- Circulating tumour cells as a window into lethality in prostate cancer.Nature reviews. Urology · 2026Review
- Circulating tumour cells for the prediction of the response to radiation therapy in prostate cancer.The British journal of radiology · 2025Review
- Liquid biopsy of circulating tumor cells: From isolation, enrichment, and genome sequencing to clinical applications.Histology and histopathology · 2025Review
- Circulating Tumor Cells: Origin, Role, Current Applications, and Future Perspectives for Personalized Medicine.Biomedicines · 2024Review
- Liquid Biopsy in the Clinical Management of Cancers.International journal of molecular sciences · 2024Review
- In vivo detection demonstrates circulating tumor cell reduction instead of baseline number has prognostic value in bladder cancer patients receiving neoadjuvant chemotherapy.Cellular oncology (Dordrecht, Netherlands) · 2023Article
- Detection and Molecular Characterization of Circulating Tumour Cells: Challenges for the Clinical Setting.Cancers · 2023Review
- In vivo detection of circulating tumor cells predicts high-risk features in patients with bladder cancer.Medical oncology (Northwood, London, England) · 2023Article
- Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors.Cancer metastasis reviews · 2023Review
- Development and clinical validation of a microfluidic-based platform for CTC enrichment and downstream molecular analysis.Frontiers in oncology · 2023Article
- Liquid Biopsy-Guided Interventional Oncology: A Proof of Concept with a Special Focus on Radiotherapy and Radiology.Cancers · 2022Review
- Review
- Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients.Journal of personalized medicine · 2021Review
- Article
- Research Progress for the Clinical Application of Circulating Tumor Cells in Prostate Cancer Diagnosis and Treatment.BioMed research international · 2021Review
- The Epstein criteria predict for organ-confined prostate cancer but not for minimal residual disease and outcome after radical prostatectomy.Turkish journal of urology · 2020Article
- The CAPRA-S score versus subtypes of minimal residual disease to predict biochemical failure after radical prostatectomy.Ecancermedicalscience · 2020Article
- The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy.Ecancermedicalscience · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
Abstract
The characterization of circulating tumor cells (CTCs) can lead to a promising strategy for monitoring residual or relapsing prostate cancer (PCa) after local therapy. The aim of this study was to compare three innovative technologies for CTC enumeration in 131 high-risk patients with PCa, before and after radiotherapy, combined with androgen deprivation. The CTC number was tested using the FDA-cleared CellSearch
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.